Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates

Yeonseon Lee, Kyung-Tae Lee, Soo Jung Lee, Ji Yoon Beom, Areum Hwangbo, Jin A Jung, Myoung Chong Song, Young Ji Yoo, Sang Hyeon Kang, Anna F. Averette, Joseph Heitman, Yeo Joon Yoon, Eunji Cheong, Yong-Sun Bahn
Yeonseon Lee
aDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyung-Tae Lee
aDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soo Jung Lee
aDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ji Yoon Beom
bDepartment of Chemistry and Nanoscience, Ewha Womans University, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Areum Hwangbo
aDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin A Jung
bDepartment of Chemistry and Nanoscience, Ewha Womans University, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myoung Chong Song
bDepartment of Chemistry and Nanoscience, Ewha Womans University, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Myoung Chong Song
Young Ji Yoo
ciNtRON Biotechnology, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sang Hyeon Kang
ciNtRON Biotechnology, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna F. Averette
dDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA
eDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, USA
fDepartment of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Heitman
dDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA
eDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, USA
fDepartment of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yeo Joon Yoon
bDepartment of Chemistry and Nanoscience, Ewha Womans University, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eunji Cheong
aDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong-Sun Bahn
aDepartment of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01627-18
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Chemical structures of FK506 and its analogs used in this study. Modifications to the FK506 structure are highlighted in red (39, 40).

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    The immunosuppressive effect of the FK506 analogs was reduced compared with that of FK506. (A) The immunosuppressive effect of FK506 on primary CD4+ T helper cells was assessed at various concentrations of FK506 with three replicates using flow cytometry. (First row) Lymphocytes were selected within the boundaries from the forward scatter area (FSC-A) and side scatter area (SSC-A); (2nd row) single cells (within the red box) were selected from the forward scatter height (FSC-H) and forward scatter area (FSC-A) for further analysis; (3rd row) primary cultured T cells from mice were stained with LIVE/DEAD cell viability kits, and the percentage of live cells was determined in the presence of various concentrations of FK506; (4th row) CD4+ helper T cells were isolated with CD4 T-cell enrichment kits. The assay included a negative-control group with inactivated T cells (NC), a positive-control group with activated T cells (PC), and a vehicle group with activated T cells and a concentration of 0 μg/ml. (B) The cytotoxicity of FK506 and its analogs is shown by the percentage of live cells treated with 0.00001 to 1 μg/ml FK506 and its analogs normalized to the number of live cells treated with vehicle. FK506 at 0.001 μg/ml significantly reduced cell viability by ∼50%, whereas none of the FK506 analogs at the same concentration showed any cytotoxicity. (C) CellTrace Violet (CTV) was used to dye the cells immediately following culture, and intensity levels were measured to detect proliferation after 72 h of drug exposure. The experiment was performed with three replicates for each concentration of each analog compound tested across a range of concentrations. Multiple peaks indicating the proliferation of T cells diminished at concentrations associated with immune suppression. The percentage of proliferating cells within each group was normalized to the number of cells treated with the vehicle. (D) Data from three independent biological groups were used to calculate the IC50 for each compound using nonlinear regression fit analysis. Curves for all compounds displayed higher IC50s compared with the IC50 of FK506, which indicated a significant reduction in immunosuppressive activity. All data are presented as the mean ± standard error of the mean (SEM).

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    All FK506 analogs, except for 9-deoxo-prolyl-FK506, exhibited dose-dependent antifungal activity against C. neoformans. (A) Disk diffusion halo assays revealed enhanced inhibition of C. neoformans with treatment with FK506 and its analogs. A total of 2 × 107 wild-type (H99 strain) cells were resuspended in top agar and poured onto yeast extract-peptone-dextrose (YPD) solid medium. The disks contained 0.1, 1, or 10 μg of FK506 and its analogs. All the FK506 analogs, except for 9DP-FK506, significantly enhanced halo clearing in a concentration-dependent manner at 37°C. (B) MIC test using 2-fold serially diluted FK506 and FK506 analogs from 15 μg/ml. 9D-FK506, 9D31OD-FK506, and 31OD-FK506 suppressed the growth of nine C. neoformans isolates. (C) MCC1 (frr1::ADE2 mutant) was resistant to 30 μg/ml of FK506, 60 μg/ml of 9D-FK506, 100 μg/ml of 9DP-FK506, 60 μg/ml of 9D31OD-FK506, and 40 μg/ml of 31OD-FK506, whereas its background strain (ade2Δ mutant M049) and H99 cells were susceptible at 37°C. (D) Each C. neoformans strain (the H99 wild-type [WT], cna1Δ, cnb1Δ, and ire1Δ strains) was grown overnight, 10-fold serially diluted, and spotted onto YPD medium with or without 1 μg/ml of the FK506 analogs and 0.2 μg/ml of tunicamycin (TM). (E) Synergism between fludioxonil and the FK506 analogs. A disk diffusion assay was performed with FK506, its analogs (4 μg of FK506 and 31OD-FK506 and 6 μg of 9D-FK506, 9DP-FK506, and 9D31OD-FK506), and fludioxonil at 30°C. DMSO, dimethyl sulfoxide; FDX10 and FDX100, 10 and 100 μg fludioxonil, respectively.

  • FIG 4
    • Open in new tab
    • Download powerpoint
    FIG 4

    All FK506 analogs, except for 9-deoxo-prolyl-FK506, exhibited antifungal activity against C. albicans SC5314. (A) Growth of C. albicans (10-fold serially diluted from an OD of 1.0) on 50% FBS agar containing 3 μg/ml of FK506 or its analogs (5 μg/ml 9D-FK506, 10 μg/ml 9D31OD-FK506, 10 μg/ml 9DP-FK506, or 3 μg/ml 31OD-FK506) at 37°C for 24 h. Growth was suppressed compared with that of the nontreated control. All FK506 analogs, except for 9-deoxo-prolyl-FK506, resulted in reduced growth rates over 1 day. (B) MIC test using 2-fold serially diluted FK506 and FK506 analogs from 10 μg/ml.

  • FIG 5
    • Open in new tab
    • Download powerpoint
    FIG 5

    All FK506 analogs, except for 9-deoxo-prolyl-FK506, exhibited antifungal activity against A. fumigatus Af293. (A) Growth of A. fumigatus (5,000 spores/2 μl) on YPD containing 1 μg/ml of FK506 or its analogs at 37°C for 3 days. The diameter of each colony differed from that of the nontreated control. All FK506 analogs reduced the growth rate across 3 days, except for 9DP-FK506. (B) MIC test using 2-fold serially diluted FK506 and its analogs from 50 μg/ml.

  • FIG 6
    • Open in new tab
    • Download powerpoint
    FIG 6

    Calcineurin inhibitors exhibited synergistic antifungal activity with azoles against C. neoformans and C. albicans. (A) Disk diffusion halo assays demonstrated enhanced inhibition of C. neoformans when fluconazole and voriconazole were combined with the FK506 analogs. Wild-type (H99) cells were grown in YPD medium overnight. For each strain, 2.5 × 107 cells/ml were resuspended in top agar (10 ml) and poured onto YPD solid medium (20 ml). Cells were incubated for 48 h at 30 and 37°C. FK506 (2 μg) exhibited synergistic antifungal effects at 37°C when combined with 1 μg of voriconazole or 25 μg of fluconazole. Castor oil solution (5 μl) was used as a negative control. (B) C. albicans (SC5314) cells were grown in YPD medium overnight. The 2-fold serially diluted cells were spotted onto YPD containing 1 μg/ml of FK506, 9-deoxo-FK506 (9D-FK506), 9-deoxo-31-O-demethyl-FK506 (9D31OD-FK506), and 31-O-demethyl-FK506 (31OD-FK506) with or without fluconazole, voriconazole, or itraconazole. (C) FIC assay of FK506, 9D31OD-FK506, and 31OD-FK506 with fluconazole. C. neoformans cells were grown in YPD medium overnight and diluted in liquid RPMI 1640 medium to 0.01 OD unit/ml. The drugs were 2-fold serially diluted from the indicated concentrations. FCZ, fluconazole; VCZ, voriconazole; ITZ, itraconazole.

  • FIG 7
    • Open in new tab
    • Download powerpoint
    FIG 7

    In vivo efficacy analysis of the FK506 analogs. The C. neoformans cells cultured overnight were washed twice with PBS, and the number of cells was synchronized. (A) In vivo efficacy test using a Galleria mellonella insect model. Amphotericin B (AMB), FK506, and the FK506 analogs were used at 5 mg/kg, and insects were treated three times at 24, 48, and 72 h after inoculation. (B) In vivo efficacy test in a murine model. Cells (5 × 105) were used to infect each mouse via intravenous inoculation. The concentrations of fluconazole (FCZ), FK506, and 9-deoxo-31-O-demethyl-FK506 (9D31OD-FK506) were 3 mg/kg, and the combination group was treated with a mixture of 3 mg/kg of 9D31OD-FK506 with 3 mg/kg of FCZ. The log-rank (Mantel-Cox) test was used for statistical analysis.

  • FIG 8
    • Open in new tab
    • Download powerpoint
    FIG 8

    Crystal structures of FKBP12 and alignment of FKBP12 sequences. (A) Superimposition of the FKBP12-FK506 structures of Homo sapiens (PDB accession number 1FKJ), C. albicans (PDB accession number 5HW8), and A. fumigatus (PDB accession number 5HWC). (B) Sequence alignments of the FKBP12s of H. sapiens, C. neoformans, C. albicans, and A. fumigatus. The secondary structure of FKBP12 is shown above the sequence. Key residues for binding between FKBP12 and FK506 are labeled with a box. Identical and highly conserved residues are highlighted in orange and yellow, respectively. (C) Binding mode of FK506 within the hydrophobic pocket of human FKBP12 (PDB accession number 1FKJ).

Tables

  • Figures
  • Additional Files
  • TABLE 1

    Summary of cytotoxicity, immunosuppressive activity, and antifungal activity of FK506 structural analogsa

    FK506 analogConcn for 50% cytotoxicity (μg/ml)Concn for 50% immunosuppression (ng/ml)Cryptococcus neoformansCandida albicansAspergillus fumigatus
    IC50 (μg/ml)Avg IC50 (μg/ml)IC50 (μg/ml)Avg IC50 (μg/ml)IC50 (μg/ml)Avg IC50 (μg/ml)
    FK506≃0.0010.0270.0010.00070.0050.012080.0150.0313
    9DP-FK506>1268.3004.813>12.5322.000>10>50.000>50
    9D-FK50610.5130.0390.00160.9631.41024.1904.6340
    31OD-FK506>10.2460.0070.00180.1060.086960.1650.1797
    9D31OD-FK506>115.0900.1750.00262.7963.23929.77019.5500
    • ↵a Abbreviations: 9DP-FK506, 9-deoxo-prolyl-FK506; 9D-FK506, 9-deoxo-FK506; 31OD-FK506, 31-O-demethyl-FK506; 9D31OD-FK506, 9-deoxo-31-O-demethyl-FK506; IC50, 50% inhibitory concentration.

Additional Files

  • Figures
  • Tables
  • Supplemental material

    • Supplemental file 1 -

      Supplemental Figure S1 and Table S1

      PDF, 4.2M

PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates
Yeonseon Lee, Kyung-Tae Lee, Soo Jung Lee, Ji Yoon Beom, Areum Hwangbo, Jin A Jung, Myoung Chong Song, Young Ji Yoo, Sang Hyeon Kang, Anna F. Averette, Joseph Heitman, Yeo Joon Yoon, Eunji Cheong, Yong-Sun Bahn
Antimicrobial Agents and Chemotherapy Oct 2018, 62 (11) e01627-18; DOI: 10.1128/AAC.01627-18

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates
Yeonseon Lee, Kyung-Tae Lee, Soo Jung Lee, Ji Yoon Beom, Areum Hwangbo, Jin A Jung, Myoung Chong Song, Young Ji Yoo, Sang Hyeon Kang, Anna F. Averette, Joseph Heitman, Yeo Joon Yoon, Eunji Cheong, Yong-Sun Bahn
Antimicrobial Agents and Chemotherapy Oct 2018, 62 (11) e01627-18; DOI: 10.1128/AAC.01627-18
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

calcineurin
FKBP12
human fungal pathogen
calcium signaling
immunosuppressant

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596